ICD-10-CM Billable Code

E71.53

Other group 2 peroxisomal disorders

Clinical Classification Guidelines

Medical Intelligence & Overview

Other Group 2 peroxisomal disorders, classified under ICD-10 code E71.53, are a rare group of inherited conditions that affect the function of peroxisomes—tiny structures within cells that are vital for breaking down certain molecules. These disorders disrupt normal metabolism, leading to a variety of health issues. While they are uncommon, understanding their nature can help in managing symptoms and improving quality of life.

Causes & Symptoms

Clinical Causes: These disorders are caused by genetic mutations that lead to defects in specific enzymes or proteins necessary for peroxisomes to function properly. They are inherited in an autosomal recessive manner, meaning that a person must inherit two copies of the defective gene—one from each parent—to be affected. The precise genetic mutations vary among individuals, contributing to the diversity seen within this group of disorders.

Key Symptoms: Symptoms can vary considerably depending on the severity and specific defect involved, but common features include: - Developmental delays or intellectual disabilities - Hypotonia (reduced muscle tone) - Delayed speech and motor skills - Vision problems, such as cataracts or retinal degeneration - Hearing loss - Accumulation of very long-chain fatty acids in tissues, which may lead to organ dysfunction - Liver enlargement and issues with the liver - Skeletal abnormalities, including growth delays - Seizures in some cases Since symptoms are broad and can overlap with other neurological or metabolic disorders, proper medical evaluation is essential for accurate diagnosis.

Diagnostic & Treatment

Diagnosis Path: Diagnosing other group 2 peroxisomal disorders involves a combination of genetic testing, biochemical analysis, and clinical evaluation. Key steps include: - Blood tests to measure levels of very long-chain fatty acids - Genetic testing to identify specific mutations in genes related to peroxisomal function - Imaging studies, such as MRI, to assess brain development and detect any structural abnormalities - Neurodevelopmental assessments to gauge cognitive and motor development Early diagnosis is vital for managing symptoms and exploring potential treatment options.

Treatment Protocols: Currently, there is no cure for other group 2 peroxisomal disorders. Treatment focuses on managing symptoms and preventing complications, which may include: - Supportive therapies like physical, occupational, and speech therapy to improve motor skills and communication - Regular monitoring of organ function, especially liver and neurological health - Nutritional interventions to support overall health - Management of seizures if present - Specialized medical care tailored to individual needs Research into potential therapies, including enzyme replacement and gene therapy, is ongoing, holding hope for future treatment options.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is E71.53 a billable ICD-10 code?
Yes, E71.53 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report E71.53?
Clinical documentation must specify the nature of Other group 2 peroxisomal disorders and any associated comorbidities for accurate reporting.

Cite this Clinical Reference